{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Moreira D"],"funding":["NCI NIH HHS","Department of Defense"],"pagination":["5948-5962"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6279477"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["24(23)"],"pubmed_abstract":["<h4>Purpose</h4>Prostate cancers show remarkable resistance to emerging immunotherapies, partly due to tolerogenic STAT3 signaling in tumor-associated myeloid cells. Here, we describe a novel strategy combining STAT3 inhibition with Toll-like Receptor 9 (TLR9) stimulation to unleash immune response against prostate cancers regardless of the genetic background.<h4>Experimental design</h4>We developed and validated a conjugate of the STAT3 antisense oligonucleotide (ASO) tethered to immunostimulatory TLR9 agonist (CpG oligonucleotide) to improve targeting of human and mouse prostate cancer and myeloid immune cells, such as myeloid-derived suppressor cells (MDSC).<h4>Results</h4>CpG-STAT3ASO conjugates showed improved biodistribution and potency of STAT3 knockdown in target cells <i>in vitro<"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers."],"pmcid":["PMC6279477"],"funding_grant_id":["R01 CA213131","P30 CA033572","W81XWH-16-1-0499"],"pubmed_authors":["Swiderski P","Pal SK","Moreira D","Zhang Z","Lu X","Su YL","White SV","Adamus T","DePinho RA","Zhao X","Kortylewski M"],"additional_accession":[]},"is_claimable":false,"name":"STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers.","description":"<h4>Purpose</h4>Prostate cancers show remarkable resistance to emerging immunotherapies, partly due to tolerogenic STAT3 signaling in tumor-associated myeloid cells. Here, we describe a novel strategy combining STAT3 inhibition with Toll-like Receptor 9 (TLR9) stimulation to unleash immune response against prostate cancers regardless of the genetic background.<h4>Experimental design</h4>We developed and validated a conjugate of the STAT3 antisense oligonucleotide (ASO) tethered to immunostimulatory TLR9 agonist (CpG oligonucleotide) to improve targeting of human and mouse prostate cancer and myeloid immune cells, such as myeloid-derived suppressor cells (MDSC).<h4>Results</h4>CpG-STAT3ASO conjugates showed improved biodistribution and potency of STAT3 knockdown in target cells <i>in vitro<","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Dec","modification":"2025-04-19T01:49:06.427Z","creation":"2020-10-29T17:03:36Z"},"accession":"S-EPMC6279477","cross_references":{"pubmed":["30337279"],"doi":["10.1158/1078-0432.CCR-18-1277","10.1158/1078-0432.ccr-18-1277"]}}